SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TOSHI

TOSHI is trending as the community speculates on potential catalysts and future gains, with some mentioning a possible Binance or Robinhood listing. Bullish investors are actively buying the dips, citing the project's utility and strong community as reasons for their optimism. Others highlight the potential for significant growth, drawing comparisons to previous meme coin successes and the overall positive sentiment surrounding the Base ecosystem.

this coin is scarce

SCARCE CRYPTO is trending as community members express excitement and encourage others to buy, emphasizing the coin's scarcity. Discussions highlight a controlled chart and smooth range, with some suggesting the coin is poised for a breakout. The coin is also being mentioned alongside other cryptos such as SOL and BTC.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Strike Coin

Starknet ($STRK) is trending as community members highlight its potential role in scaling Bitcoin and Ethereum through zero-knowledge proofs, with some drawing comparisons to Zcash ($ZEC). Discussions also focus on Starknet's ecosystem growth, recent technical upgrades including the S-Two STARK prover, and incentives for Bitcoin liquidity staking, suggesting a growing interest in its capabilities and future prospects.

AKUMA INU was born in BASE, the underground arena that has come to be known amongst crypto degens as "The Origin Pit". Forged in the frenzied fires of market volatility, AKUMA INU has emerged as the ultimate embodiment of the degen spirit - wild, unyielding, and relentless in the pursuit of crypto supremacy. Akuma Inu is here on Base chain, and he is here to stay. Come join us on our amazing journey!

Akuma Inu

Akuma Inu is trending as a micro-cap gem with a low market capitalization gains traction within the community. Discussions highlight its potential for explosive growth, drawing comparisons to its previous all-time highs. Community members are pointing out the coin's potential for significant returns.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

Canadian Solar is trending due to a surge in stock price, fueled by optimism around its energy storage solutions and potential benefits from the AI-driven data center boom. Community discussions highlight the undervaluation of CSIQ compared to its assets, particularly its stake in CSI Solar, and speculate about a potential sale of Recurrent Energy. The stock's recent performance has also led to discussions of a possible short squeeze.

DoubleZero is a high-performance global network of independently contributed links, purpose-built for blockchain and other distributed systems. It provides direct, low-latency routing that strengthens validator performance and supports faster, fairer participation worldwide.  2Z Tokens are used to access the network’s connectivity service, and, on the other side, reward network contributors and resource providers based on performance and reliability. 2Z Tokens can also be staked to enhance the security of the network.

DoubleZero

DoubleZero ($2Z) is trending amid discussions about its potential in crypto telecom, particularly its use of fiber optics. Community members are weighing in on its recent price action, with some citing a new listing on a major crypto exchange driving volume, while others debate its legitimacy.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders discuss potential market volatility catalysts, including housing market concerns, foreclosure rates, and geopolitical risks. Community members are actively sharing options strategies and hedging techniques, while also debating the differences between UVIX and similar volatility products like UVXY. Some traders express skepticism about current market valuations, anticipating a potential market correction and increased volatility.

Cummins, Inc. engages in the design, manufacture, and distribution of diesel, natural gas, electric and hybrid powertrains and powertrain-related components including filtration, aftertreatment, turbochargers, fuel systems, valvetrain technologies, controls systems, air handling systems, automated transmissions, axles, drivelines, brakes, suspension systems, electric power generation systems, batteries, electrified power systems, hydrogen production technologies, and fuel cell products. It operates through the following segments: Engine, Distribution, Components, Power Systems, and Accelera. The Engine segment manufactures and markets diesel and natural gas-powered engines under the Cummins brand name, for the heavy- and medium-duty truck, bus, recreational vehicle, light-duty automotive, construction, mining, marine, rail, oil and gas, defense, and agricultural markets. The Distribution segment includes power generation systems, high-horsepower engines, heavy-duty and medium-duty engines designed for on- and off-highway use, application engineering services, custom-designed assemblies, retail and wholesale aftermarket parts, and in-shop and field-based repair service. The Components segment supplies products including axles, drivelines, brakes and suspension systems for commercial diesel and natural gas applications, aftertreatment systems, turbochargers, fuel systems, valvetrain technologies, filtration products, automated transmissions, and electronics. The Power Systems segment engages in power generation, industrial, and generator technologies. The Accelera segment designs, manufactures, sells, and supports hydrogen production technologies, as well as electrified power systems, including battery, fuel cell, and electric powertrain technologies. The company was founded by Clessie Lyle Cummins and William Glanton Irwin on February 3, 1919 and is headquartered in Columbus, IN.

Cummins Inc.

Cummins is trending following an analyst upgrade from Wells Fargo, sparking bullish sentiment and a new price target among investors. Community members are actively discussing the stock's strong market context, potential resistance ahead, and possible collaboration with other companies like Ford in the clean energy sector. Technical analysis suggests a bullish trend, though some caution against overextension due to the stock nearing overbought territory.

What is the project about?   Horizen is a modular privacy-first platform designed to make privacy technology, such as zero-knowledge proofs and TEEs accessible and usable across the web. Originally launched in 2017 as a fair launch, non-ICO project, Horizen is now undergoing a major evolution with the launch of Horizen 2.0, a next-generation Layer 3 (L3) appchain deployed on Base, the Ethereum Layer 2 developed by Coinbase.  Horizen 2.0 is built as an Ethereum-aligned Layer 3 appchain on Base, inheriting Ethereum's security while implementing its own application-level integrity guarantees.    Key components of Horizen’s security model include:  Ethereum-Aligned Security: As an appchain deployed on Base, Horizen 2.0 benefits from Base’s rollup security and settlement on Ethereum, ensuring robust finality and composability with other L2 and L3 applications.  Simplified and Secure Architecture: Unlike Horizen’s previous iterations (which used a hybrid PoW/PoS model), Horizen 2.0 focuses on application-level security, decentralization of its privacy layers, and composability with existing infrastructure — reducing complexity and increasing user safety.  Decentralized Privacy Stack: Horizen’s focus on decentralizing privacy infrastructure (e.g., decentralized proof generation) allows for modular, secure applications that uphold data confidentiality without compromising performance.    What makes your project unique?  Privacy-first Approach: Horizen integrates a diverse stack of privacy-enhancing technologies (PETs) — including zero-knowledge proofs (ZKPs), trusted execution environments (TEEs), attribute-based encryption (ABE), multi-party computation (MPC), and fully homomorphic encryption (FHE) — to deliver scalable, flexible, and future-ready privacy solutions across its platform.  First Privacy Appchain on Base: As an L3 on Base, Horizen benefits from Ethereum’s security and Base’s scalability, while enabling a privacy layer for any app on the network. This unlocks new possibilities for private identity, DeFi, onchain gaming, and compliant confidential transactions.  Zero-Knowledge, Without the Trade-Offs: Horizen 2.0 scales ZK privacy and verification by integrating with leading zk infrastructure providers such as Fermah, zkVerify, and Singularity, optimizing proof generation for performance, cost-efficiency, and developer usability.  Token Utility Expansion: ZEN’s updated tokenomics allocates 5 million unminted tokens toward strategic ecosystem growth. ZEN powers DAO governance, serves as a payment token in privacy apps, and supports a sustainability fund to accelerate privacy innovation.  Developer-Centric Design: With EVM compatibility, privacy-friendly tooling, and the ability to embed privacy directly into smart contracts, Horizen allows developers to build privacy-first apps without requiring deep cryptographic expertise.  DAO-Led Governance: Governed by the Horizen DAO and shaped through community proposals (ZENIPs), Horizen is evolving as a fully decentralized protocol with transparent development and decision-making.    What can your coin/token be used for?  Horizen 2.0 delivers performance, privacy, and scalability for developers building privacy-enabled and compliance-friendly applications, with significantly reduced cost and latency.  At the core of the ecosystem is ZEN, the native utility token used for governance, accessing privacy services, and fueling zkApp interactions. With its migration to Base, ZEN becomes an ERC-20 token, improving liquidity, interoperability, and composability across the broader Ethereum ecosystem.

ZenCash

ZEN Crypto is trending as traders discuss its potential for significant gains, drawing comparisons to ZCash ($ZEC). Community members are actively watching key price levels, anticipating a pump and citing its limited supply as a factor for potential growth. The migration to Base chain and listing on OKX exchange is also a key catalyst.

CME Group, Inc. operates a derivatives marketplace, which offers a range of futures and options products for risk management. Its exchanges offer a range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange (FX), energy, agricultural commodities and metals. It offers futures and options on futures trading across asset classes through the CME Globex platform, fixed income trading via BrokerTec and FX trading on the EBS platform. In addition, it also operates CME Clearing, a central counterparty clearing provider. The company was founded in 1898 and is headquartered in Chicago, IL.

CME Group Inc - Ordinary Shares - Class A

CME Group Inc

CME is trending amid discussions around market volatility, potential interest rate impacts, and technical analysis suggesting both bullish and bearish signals. Traders are weighing the stock's reaction to overall market conditions and potential new product launches in the crypto derivatives space. Options activity and analyst ratings are also contributing to the ongoing conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sanjay Singh Sells 18,777 Shares of MannKind (NASDAQ:MNKD) Stock

MannKind Corporation (NASDAQ:MNKD - Get Free Report) EVP Sanjay Singh sold 18,777 shares of the company's stock in a transaction on Friday, November 14th. The shares were sold at an average price of...

MannKind (NASDAQ:MNKD) Now Covered by Leerink Partners

Leerink Partners initiated coverage on MannKind in a report on Thursday. They set an "outperform" rating and a $7.00 price target for the company...

Wedbush Forecasts MannKind's FY2025 Earnings (NASDAQ:MNKD)

MannKind Corporation (NASDAQ:MNKD - Free Report) - Equities research analysts at Wedbush increased their FY2025 EPS estimates for shares of MannKind in a research note issued on Monday, November...

Royal Bank Of Canada Has Lowered Expectations for MannKind (NASDAQ:MNKD) Stock Price

Royal Bank Of Canada decreased their price target on MannKind from $8.00 to $7.50 and set an "outperform" rating for the company in a research note on Tuesday...

MannKind (NASDAQ:MNKD) Price Target Lowered to $8.00 at Wells Fargo & Company

Wells Fargo & Company reduced their price objective on shares of MannKind from $10.00 to $8.00 and set an "overweight" rating on the stock in a research note on Tuesday...

Los Angeles Capital Management LLC Buys 177,440 Shares of MannKind Corporation $MNKD

Los Angeles Capital Management LLC lifted its position in MannKind Corporation (NASDAQ:MNKD - Free Report) by 68.3% during the second quarter, according to the company in its most recent Form 13F...

MannKind (NASDAQ:MNKD) Shares Gap Down - Here's What Happened

MannKind (NASDAQ:MNKD) Shares Gap Down - What's Next...

MannKind (NASDAQ:MNKD) Announces Quarterly Earnings Results

MannKind (NASDAQ:MNKD - Get Free Report) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus...

MannKind (NASDAQ:MNKD) Shares Gap Up After Better-Than-Expected Earnings

MannKind (NASDAQ:MNKD) Shares Gap Up Following Earnings Beat...

<ul class="summary-bullets"><li>MannKind’s stock has gained momentum amid optimism over its expanding diabetes portfolio and 2026 milestones.</li><li>CEO Michael Castagna said the FDA has accepted its Afrezza pediatric application, potentially making it the first new insulin for U.S. children in a century.</li><li>MannKind is reviving its BlueHale smart inhaler and expanding in the $5.6 billion pediatric diabetes management market, according to Grand View Research.</li></ul><p>MannKind shares are closing in on a breakout after a record quarter, with investors betting on its Afrezza pediatric approval — the first new insulin for U.S. children in a century — and the return of its connected inhaler platform, BlueHale.</p><h2 class="st-heading-2"><strong>Shares Rebound Toward Breakout Zone</strong></h2><p>Shares of MannKind have surged nearly 80% from their August low of $3.42, closing Wednesday at $6.06, within 6% of where they began the year, as investors focus on Afrezza’s next phase of growth and a series of 2026 milestones. The stock hit its highest levels in over 9 months on Wednesday and logged its best&nbsp;session in more than 2 months.&nbsp;</p><p>The company reported&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mannkind-stock-soar-after-upbeat-quarterly-earnings/cL2qn70REGU">record third-quarter (Q3) revenue</a> of $82 million, led by a 23% year-over-year rise in Afrezza inhaled insulin sales. Adjusted earnings of $0.07 per share beat consensus estimates of $0.02, according to Fiscal AI data.</p><h2 class="st-heading-2"><strong>Afrezza’s Pediatric Push&nbsp;</strong></h2><p>MannKind said the FDA has accepted its supplemental application to expand Afrezza to children aged 4 to 17, with a decision expected by May 2026. On the company’s Q3 earnings call, CEO Michael Castagna described the filing as a potential milestone that could make Afrezza the first new insulin for U.S. pediatric patients in more than a century.</p><p>Insulin therapy dates to 1922, when a 14-year-old boy became the first patient successfully treated, transforming type 1 diabetes from a fatal illness into a manageable condition, according to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8802620/">Nature Medicine study</a> archived by the U.S. National Library of Medicine.</p><p>The global pediatric diabetes management market, which includes devices, monitoring systems, and therapeutics for children and adolescents with diabetes, was valued at about $5.59 billion in 2024 and is projected to reach $13.11 billion by 2033, according to&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.grandviewresearch.com/industry-analysis/pediatric-diabetes-management-market-report">Grand View Research</a>.</p><p>To prepare for the pediatric opportunity, MannKind is expanding its field and medical liaison teams, focusing on top pediatric diabetes centers, including Joslin Diabetes Center in Boston and the Barbara Davis Center in Denver.</p><p>The company also plans to roll out an updated Afrezza dose-conversion label early next year. Castagna said the change will help new prescribers correctly dose patients from the start and address “lack of effect,” which is the most common early complaint.</p><h2 class="st-heading-2"><strong>BlueHale Smart Inhaler Revived</strong></h2><p>MannKind is also reviving its BlueHale smart inhaler, which is a connected device that tracks insulin doses and integrates with continuous glucose monitors (CGMs). The latest version will feature reminders, dosing analytics, and time-in-range tracking to help patients and caregivers manage insulin use. The company plans to test BlueHale in its upcoming Inhaled First pediatric study, which aims to establish Afrezza as a first-choice bolus insulin for newly diagnosed youth with Type 1 diabetes.</p><h2 class="st-heading-2"><strong>Cardiometabolic Expansion And Pipeline Progress</strong></h2><p>In addition to diabetes, MannKind said the acquisition of scPharmaceuticals has strengthened its cardiometabolic portfolio.</p><p>A major milestone this quarter was the submission of the sNDA for the Furoscix ReadyFlow auto-injector. Upon approval, the Furoscix ReadyFlow auto-injector will simplify admissions, increase treatment options, and lower the cost of goods, creating capital that can be reinvested for growth and margin improvement.</p><p>The company is also advancing bumetanid DPI (MNKD-701) into preclinical development. Castagna said the inhaled formulation could serve patients who prefer inhaling rather than injecting. MannKind’s Technosphere platform has previously demonstrated IV-like onset and sustained efficacy in programs for insulin, treprostinil, and migraine, which the company believes supports the viability of MNKD-701.</p><h2 class="st-heading-2"><strong>Afrezza Upgrade Spurs Optimism On Stocktwits</strong></h2><p>On Stocktwits, retail sentiment for MannKind was ‘extremely bullish’ amid a 360% surge in 24-hour message volume.</p><figure class="image"><img style="aspect-ratio:967/139;" src="https://news.stocktwits-cdn.com/mnkd_ss_jpg_0feeeb3429.webp" alt="mnkd ss.jpg" width="967" height="139"><figcaption>MNKD sentiment and message volume as of November 5 | Source: Stocktwits</figcaption></figure><p>One user highlighted that MannKind’s upcoming Afrezza label update and the introduction of 2-unit cartridges could make dosing easier, improve “time in range,” and ultimately demonstrate Afrezza’s superiority over traditional insulins in future studies.</p><p><stembedurl>https://stocktwits.com/jlonards/message/635113690</stembedurl></p><p>Another user described MannKind as a “deliberate, step-by-step growth story,” adding that they plan to increase their position in the stock next week.</p><p><stembedurl>https://stocktwits.com/TwitsNelson123/message/635111816</stembedurl></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Shares of MannKind (MNKD) have surged nearly 80% from their August low of $3.42. (Photo credit: Getty Images)

MannKind Stock Nears Breakout As FDA Reviews First New Insulin For Kids In A Century

MannKind’s stock has gained momentum amid optimism over its expanding diabetes portfolio and 2026 milestones.

Equity

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$5.17
Prev Close	$5.07
Open	$5.00
Dividend Yield	0.00%
50-Day Moving Average	$5.43
Beta	0.92
Avg. Volume	4.53M
PE Ratio	53.66

52-Week High	$7.07
52-Week Low	$3.38
Market Capitalization	$1.55B
EPS (Annual)	$0.0972
Price to Book	-34.87
Revenue Per Employee	$701,484.03
Enterprise Value/EBITDA	N/A

MNKD
Mannkind Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MNKD News

MNKDMannkind Corp